115 related articles for article (PubMed ID: 10558049)
1. When should low-molecular-weight heparin be monitored?
Fairweather RB
CAP Today; 1999 Jul; 13(7):48-50. PubMed ID: 10558049
[No Abstract] [Full Text] [Related]
2. How should we define major bleeding events in thromboprophylaxis?
Bottaro FJ; Ceresetto JM
J Bone Joint Surg Am; 2010 Nov; 92(15):2617-8; author reply 2618-9. PubMed ID: 21048185
[No Abstract] [Full Text] [Related]
3. Evidence-based evaluation of preoperative vs postoperative use of low-molecular-weight heparin in preventing deep vein thrombosis in elective hip surgery.
Ghosh A
Arch Intern Med; 1999 Jul; 159(14):1622-3. PubMed ID: 10421287
[No Abstract] [Full Text] [Related]
4. Summaries for patients. Low-molecular-weight heparin given for several weeks after hip surgery prevents deep venous thrombosis.
Ann Intern Med; 2001 Nov; 135(10):S-55. PubMed ID: 11757493
[No Abstract] [Full Text] [Related]
5. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
6. Does low molecular weight heparin cause less bleeding?
Thomas DP
Thromb Haemost; 1997 Dec; 78(6):1422-5. PubMed ID: 9423787
[No Abstract] [Full Text] [Related]
7. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
Greaves M;
Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
[No Abstract] [Full Text] [Related]
8. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: introduction.
Brandt JT
Arch Pathol Lab Med; 1998 Sep; 122(9):765-6. PubMed ID: 9740134
[No Abstract] [Full Text] [Related]
9. In coagulation, a cascade of questions.
Check W
CAP Today; 1998 Jan; 12(1):1, 22-8, 29-38. PubMed ID: 10176513
[No Abstract] [Full Text] [Related]
10. LMWH and renal failure: bleeding. Creatinine clearance should be checked before choosing heparin products.
Prescrire Int; 2007 Dec; 16(92):251. PubMed ID: 18092423
[No Abstract] [Full Text] [Related]
11. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
Jameson SS; Rymaszewska M; Hui AC; James P; Serrano-Pedraza I; Muller SD
J Bone Joint Surg Am; 2012 Sep; 94(17):1554-8. PubMed ID: 22832942
[TBL] [Abstract][Full Text] [Related]
12. [Monitoring of coagulation during treatment with direct oral anticoagulants].
Kasper A; Lindhoff-Last E
Dtsch Med Wochenschr; 2013 Oct; 138(40):1997-2000. PubMed ID: 24065404
[No Abstract] [Full Text] [Related]
13. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
Whang PG; Lieberman JR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
[TBL] [Abstract][Full Text] [Related]
14. Long term anticoagulation with low molecular weight heparin in outpatients with side effects on oral anticoagulants.
Harenberg J; Leber G; Dempfle CE; Heene DL; Zimmermann R; Kübler W
Nouv Rev Fr Hematol (1978); 1989; 31(5):363-9. PubMed ID: 2555770
[TBL] [Abstract][Full Text] [Related]
15. Letters on management of ischemic stroke.
Porat G
Am Fam Physician; 2012 Sep; 86(6):492. PubMed ID: 23062038
[No Abstract] [Full Text] [Related]
16. [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
MMW Fortschr Med; 2003 Jun; 145(24):56. PubMed ID: 12866309
[No Abstract] [Full Text] [Related]
17. [Use of LMW heparin: information for prescribers. Update: 10 April 2002].
Agence Française de Sécurité Sanitaire Des Produits de Santé (AFSSAPS)
J Mal Vasc; 2002 Oct; 27(4):231-3. PubMed ID: 12457130
[No Abstract] [Full Text] [Related]
18. Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology .
Harenberg J; Kalodiki E; Walenga JM;
Int Angiol; 2012 Apr; 31(2):101-4. PubMed ID: 22466973
[No Abstract] [Full Text] [Related]
19. Perioperative bridging therapy for the at-risk patient on chronic anticoagulation.
Spyropoulos AC
Dis Mon; 2005; 51(2-3):183-93. PubMed ID: 15900271
[No Abstract] [Full Text] [Related]
20. [Possible effect low molecular weight heparin on survival time. New chances for cancer patients?].
MMW Fortschr Med; 2003 May; 145(19):suppl 3-4. PubMed ID: 12813994
[No Abstract] [Full Text] [Related]
[Next] [New Search]
